Physician profile
Robert Eric Warren
NPI 1457357584
$1,064.67
in general payments reported to CMS, 2019-2025
13 companies · $75.16 in 2025
The $75.16 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $39.50 · 2021: $215 · 2022: $158 · 2023: $142 · 2024: $182 · 2025: $75.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $419.78 | 2019-2025 | Clareon, Argos, Centurion |
| Biotissue Holdings INC. | $135.04 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $99.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $98.92 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $66.90 | 2022-2023 | Lotemax Sm |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.56 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $51.48 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $28.87 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $25.83 | 2022 | |
| Coopervision INC. | $24.94 | 2022 | |
| Glaukos Corporation | $19.66 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.99 | 2019 | |
| Ocular Therapeutix, INC. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.